BARDA awards $143.5 million contract to Pfenex for development of next generation anthrax vaccine
by Staff from Outbreak News Today on (#HNX4)
Pfenex Inc., announced today it has signed a five year, cost plus fixed fee contract valued at up to $143.5 million with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the advanced development of Px563L, a mutant recombinant protective antigen anthrax vaccine. "This contract for ["]
